Single dose, randomization blinded, two-period, two-treatment, twosequence, crossover, oral bioequivalence study of Mylanâ??s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford,Middlesex,TW8 9GS, UK, in Healthy adult male and female (not of childbearing potential) human volunteers under fasting conditions.

Start Date08 Jun 2022

Sponsor / Collaborator

Mylan Laboratories Ltd.

CTRI/2022/06/043078

/ Not yet recruitingNot Applicable

Single dose, randomization blinded, two-period, two-treatment, twosequence,crossover, oral bioequivalence study of Mylanâ??s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford,Middlesex, TW8 9GS, UK, in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.

Start Date08 Jun 2022

Sponsor / Collaborator

Mylan Laboratories Ltd.

CTRI/2022/02/040129

/ Not yet recruitingPhase 1

An open label, balanced, randomized, two-treatment, two-sequence, two-period, cross-over, single-dose, oral bioequivalence study of Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension 60mg/5mg/30mg (1 Ã? 5 Tablets) (Test) of Aurobindo Pharma Limited, India with Dolutegravir (GSK1349572)/Abacavir/Lamivudine Dispersible Tablets 5 mg/60 mg/30 mg (1 Ã? 5 Tablets) (Reference) of ViiV Healthcare, UK in 54 healthy, adult, male subjects under fed conditions

Start Date14 Feb 2022

Sponsor / Collaborator

AXIS Clinicals Ltd.

100 Clinical Results associated with Abacavir hydroxyacetate

100 Translational Medicine associated with Abacavir hydroxyacetate

100 Patents (Medical) associated with Abacavir hydroxyacetate

2,269

Literatures (Medical) associated with Abacavir hydroxyacetate

01 Jun 2025·ANALYTICAL BIOCHEMISTRY

Development and validation of a graphene quantum dot-based sensor for abacavir quantification via fluorescence quenching

Article

Author: Alqahtani, Taha ; Al Fatease, Adel ; Almrasy, Ahmed A ; Alqahtani, Ali

Human immunodeficiency virus (HIV) is a global health concern, and the development of effective methods for the detection and quantification of antiretroviral drugs is crucial for monitoring therapeutic efficacy and patient compliance. Herein, we present a novel approach utilizing graphene quantum dots (GQDs) for the determination of abacavir, a widely used nucleoside reverse transcriptase inhibitor in the treatment of HIV. The sensing mechanism was investigated through Stern-Volmer analysis, thermodynamics studies, and density functional theory calculations, which revealed the strong binding interactions between GQDs and abacavir via a static quenching process. Factors affecting the analytical performance, such as pH, GQDs concentration, and incubation time, were systematically optimized to achieve a linear detection range of 100-1000 ng/mL with a low detection limit of 17.49 ng/mL. The method was validated in accordance with ICH guidelines demonstrating excellent linearity, accuracy, precision, robustness and selectivity making it suitable for the quantification of abacavir in pharmaceutical formulations and biological samples. The method also demonstrated higher sensitivity and more environmentally friendly characteristics when compared to previously reported chromatographic techniques, showcasing the potential of GQDs as a superior alternative for the traditional detection approaches of pharmaceutical compounds.

03 Mar 2025·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks

Article

Abstract:

Objectives:

To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV from CoRIS, a multicentre cohort in Spain, in 2018–23.

Methods:

We used multivariable regression models to compare viral suppression (VS) (HIV RNA viral load <50 copies/mL), change in CD4 cell counts, persistence and treatment discontinuations due to adverse events (AEs), at 96 (±24) weeks after treatment initiation.

Results:

Of 2359 participants, DTG/3TC was prescribed in 472 (20.0%), bictegravir/tenofovir alafenamide (TAF)/emtricitabine (FTC) in 1134 (48.1%), DTG + tenofovir disoproxil fumarate/FTC in 300 (12.7%), DTG/abacavir/3TC in 273 (11.6%) and darunavir/cobicistat/TAF/FTC in 180 (7.6%). At 96 weeks from treatment initiation, 94.0% of participants initiating with DTG/3TC achieved VS, and the mean increase in CD4 cell counts was 295.5 cells/μL (95% CI: 269.9–321.1). During the first 96 weeks after DTG/3TC initiation, 9.8% and 1.3% discontinued their initial regimen, overall and due to AEs, respectively. In multivariable analyses, we did not find significant differences in VS or increase in CD4 cell counts among participants initiating with DTG/3TC compared with other regimens. Initiating ART with a regimen other than DTG/3TC was associated with a higher risk of treatment discontinuation, overall and due to AEs.

Conclusions:

Among treatment-naive people with HIV from this large multicentre cohort, DTG/3TC had similar effectiveness and better persistence and tolerability than those of the most frequently prescribed first-line regimens at 96 weeks.

21 Feb 2025·MEDICINE

Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study

Article

Author: Benson, Paul ; Ramgopal, Moti ; Ruane, Peter J. ; Brar, Indira ; Henry, Keith ; Berhe, Mezgebe ; Liu, Hui ; Brinson, Cynthia ; Hindman, Jason T. ; Andreatta, Kristen

Background::

The phase 3 randomized, active-controlled GS-US-380-1844 (NCT02603120) study evaluated switching to the single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC) among people with HIV-1. Previously, results from the 48-week double-blind phase showed that switching to B/F/TAF was noninferior to remaining on DTG/ABC/3TC and that B/F/TAF was well tolerated. Here, we show the long-term safety and efficacy of switching to B/F/TAF from DTG/ABC/3TC among people with HIV-1.

Methods::

Participants were virologically suppressed people with HIV-1 (HIV-1 RNA <50 copies/mL for ≥ 3 months prior to screening) receiving DTG/ABC/3TC at baseline. Participants were randomized 1:1 to switch to B/F/TAF or remain on DTG/ABC/3TC. Following 48 weeks of treatment with B/F/TAF or DTG/ABC/3TC in the double-blind phase, participants had the option to enter an open-label extension phase, during which they received B/F/TAF. Virologic, immunologic, and safety outcomes during treatment with B/F/TAF through the open-label extension up to 168 weeks, including preexisting and treatment-emergent resistance, were analyzed.

Results::

Among 547 participants in the all-B/F/TAF analysis set, virologic suppression (HIV-1 RNA < 50 copies/mL) was maintained in 99% to 100% of participants up to 168 weeks into B/F/TAF treatment, including in those with preexisting resistance; no treatment-emergent resistance was detected. CD4 cell counts remained stable during B/F/TAF treatment, with median (interquartile range) changes from baseline of −17 (−120, 65) cells/µL at week 48 and −9 (−100, 108) cells/µL at week 96. Safety and tolerability findings were consistent with previously reported findings up to week 48; most drug-related adverse events were grade 1 or 2 in severity; no new safety signals were identified.

Conclusion::

Switching to B/F/TAF from DTG/ABC/3TC was associated with continued high rates of virologic suppression up to week 168, with no treatment-emergent resistance. B/F/TAF was well tolerated throughout the study period.

News (Medical) associated with Abacavir hydroxyacetate

01 Jul 2020

·www.biospace.com

Research Roundup: Multiple Molecules that Can Shut Down COVID-19 and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones. Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones. Multiple Molecules IDed to Shut Down SARS-CoV-2 Polymerase Reaction Researchers at Columbia Engineering and the University of Wisconsin-Madison identified a library of molecules that can shut down the polymerase reaction in the SARS-CoV-2 virus that causes COVID-19. The virus uses polymerase to replicate its genome inside infected human cells. Stopping that polymerase reaction would stop the growth of the virus. Five of the molecules they identified are used for treating other viral infections, including HIV, cytomegalovirus, and hepatitis B. The research was published in the journal Antiviral Research . “In our efforts to help tackle this global emergency, we are very hopeful that the structural and chemical features of the molecules we identified, in correlation with their inhibitory activity to the SARS-CoV-2 polymerase, can be used as a guide to design and synthesize new compounds for the development of COVID-19 therapeutics,” said Jingyue Ju , Ruben-Peter G. Viele Professor of Engineering at Columbia University. “We are extremely grateful for the generous research support that enabled us to make rapid progress on this project. I am also grateful for the outstanding contributions made by each member of our collaborative research consortium.” In earlier research, they found that the active triphosphate of the hepatitis C drug sofosbuvir ( Gilead Sciences ’ Solvadi) and its derivative could potentially inhibit the polymerase in the virus. They then tested four other nucleotide analogues, the active triphosphate forms of HIV drugs Alovudine, Zidovudine, Tenofovir alafenamide, and Emtricitabine, which all inhibited the virus’s polymerase with different levels of activity. They then analyzed 11 compounds, narrowing them down to six that showed intermediate termination of the polymerase reaction, two that showed delayed termination, and three that did not terminate the polymerase. The prodrugs of the five analogues are Cidofovir, Abacavir, Valganciclovir/Ganciclovir, Stuvadine and Entacavir. COVID-19 Mutations Result in 10-Times Contagiousness Researchers at The Scripps Research Institute have found that the strains spreading so quickly in Europe and the U.S. have a mutated S “spike” protein that makes it about 10 times more infectious than the strain that originally was identified in Asia. The research was published online on bioRxiv and has yet to be peer-reviewed. The mutation does not appear to make the virus any more deadly than it already is, but it does appear to make it significantly more contagious. The original strain in China is dubbed D614, while the one found in May in the UK, Italy and North America is dubbed G614. The S “spike” protein is found on the surface of the virus and is used to gain entry to cells, something like a key in a lock. But the original strain, D614, often broke off when it was attempting to bind to ACE2 receptors in people’s airways. The mutated version, G614, is less likely to break off, allowing it to more easily make its way into cells. Microbiome Offers Resistance to Cholera The microbiome is the trillions of microorganisms that live in and on the body. Increasingly, it is found to have an effect on numerous illnesses, not just those of the gastrointestinal tract. Cholera is a potentially deadly disease that causes an extreme type of watery diarrhea. Researchers at UC Riverside identified specific gut bacteria that appear to make people resistant to cholera, which affects as many as 4 million people globally. The bacterium is Blautia obeum , which appears to deactivate the cholera bacterium’s disease-causing mechanisms. Potential Therapy to Regenerate Heart Tissue Researchers at the University of Helsinki , with a State Key Laboratory of Cardiovascular Disease at FuWai Hospital in Beijing, investigated a mouse model of artificial myocardial infraction to determine if a tissue-engineered approach would work for stimulating myocardial regeneration. They identified 1,005 proteins from the myocardium, of which 216 were expressed immediately below the atrial appendage micrograft (AAM) patches in a “subtransplant” area in the interventricular septum. This appeared to both preserve the heart’s pumping function and improve functional recovery. SARS-CoV-2 Has Ability to Infect Heart Cells Research out of Cedars-Sinai Medical Center found that SARS-CoV-2, the virus that causes COVID-19, has the ability to infect heart cells directly, at least in laboratory tests. Many COVID-19 patients do experience heart problems, which might be related to pre-existing conditions, inflammation, oxygen deprivation, or hyperactive blood clotting. But the study also found that the human stem cell-derived heart cells infected by the virus in culture changed their gene expression profile. This suggests that the cells activate innate cellular defense mechanisms in an attempt to fight the virus. “This viral pandemic is predominantly defined by respiratory symptoms, but there are also cardiac complications, including arrhythmias, heart failure and viral myocarditis,” said Clive Svendsen , co-corresponding and senior author of the study, and director of the Regenerative Medicine Institute and professor of Biomedical Sciences and Medicine. “While this could be the result of massive inflammation in response to the virus, our data suggest that the heart could also be directly affected by the virus in COVID-19.” How COVID-19 Causes Blood Clots One of the many puzzling aspects of COVID-19 is the risk, in some patients, even younger patients, of unusual blood clotting that can lead to heart attacks and strokes. Researchers at the University of Utah Health have identified inflammatory proteins produced during a COVID-19 infection that alters the function of platelets, which increases their likelihood of forming blood clots. The research was published in Blood , an American Society of Hematology journal. “Our finding adds an important piece to the jigsaw puzzle that we call COVID-19,” said Robert A. Campbell , senior author of the study and an assistant professor in the Department of Internal Medicine at the University of Utah Healthy. “We found that inflammation and systemic changes, due to the infection, are influencing how platelets function, leading them to aggregate faster, which could explain why we are seeing increased numbers of blood clots in COVID patients.” Utilizing differential gene analysis, the scientists found that SARS-CoV-2 seems to trigger genetic changes in platelets. The COVID-19 platelets in laboratory tests aggregated more quickly, and the changes significantly affected how the platelets interacted with the immune system. This contributed to inflammation of the respiratory tract, which caused more severe lung damage. What was also unusual was they did not see the virus in most of the platelets, which suggested the virus was promoting those genetic changes indirectly, possibly by way of inflammation affecting megakaryocytes, which produce platelets. In test-tube studies, at least, aspirin seemed to prevent the hyperactivity. “There are genetic processes that we can target that would prevent platelets from being charged,” Campbell said. “If we can figure out how COVID-19 is interacting with megakaryocytes or platelets, then we might be able to block that interaction and reduce someone’s risk of developing a blood clot.”

30 Oct 2018

·www.biospace.com

Janssen, Gilead Showcase HIV Data at Glasgow Conference

Janssen and Gilead Sciences continue to showcase the potential treatment abilities of their respective HIV treatments. This morning the two companies released 96-week data demonstrating their efficacy and safety that was presented during an HIV conference in the United Kingdom. Janssen and Gilead Sciences continue to showcase the potential treatment abilities of their respective HIV treatments. This morning the two companies released 96-week data demonstrating their efficacy and safety that was presented during an HIV conference in the United Kingdom. The news shared by both companies comes less than a month after they both released data showcasing the efficacy of their HIV medications . California-based Gilead announced 96-week results from a Phase III study of its HIV drug Biktarvy for the treatment of HIV-1 infection in treatment-naïve adults. In the ongoing Phase III study, Gilead said Biktarvy was found to be statistically non-inferior to a triple-combination regimen of dolutegravir and emtricitabine/tenofovir alafenamide (50 mg) through 96 weeks of therapy. The new data were presented during a late-breaking abstract session at the 2018 HIV Glasgow conference in Glasgow, Scotland. In the study, treatment-naïve adults were randomized to receive either the Gilead medication or the triple combination. At week 96, non-inferiority was maintained from the primary endpoint measurement at Week 48, with 84.1 percent of patients taking Biktarvy and 86.5 percent taking the triple combination achieving HIV-1 RNA levels less than 50 copies/mL. In the resistance analysis population, none of the study participants randomized to Biktarvy developed treatment-emergent resistance, Gilead said. That follows data released earlier this month that showed 87.9 percent of patients taking Biktarvy showed non-inferiority against 89.8 percent of patients taking a different triple combination medication of abacavir/dolutegravir/lamivudine. Biktarvy, a once-per-day treatment, was approved by the FDA in February as a complete regimen to treat HIV-1 in adults who haven’t been treated with antiretrovirals or to replace the current antiretroviral regimen in patients who are virologically suppressed on a stable antiretroviral regimen for at least three months. John McHutchison, Gilead’s chief scientific officer, said the latest data continues to demonstrate the efficacy and safety pro Biktarvy. McHutchison added that the data also supports use of the single-tablet regimen in a “broad range of adults living with HIV who are new to HIV therapy.” “Gilead is working to advance access to Biktarvy to appropriate patients around the world as we continue our clinical and research efforts focusing on novel mechanisms of action for next-generation HIV treatments and, ultimately, a cure,” McHutchison said in a statement. Janssen, a division of Johnson & Johnson , also showed off data from its HIV treatment Symtuza at the Scotland conference. Janssen also presented 96-week data that showed positive, long-term efficacy of the medication in treatment-naïve adults with HIV-1. Results from the 96-week study showed that a high proportion of antiretroviral treatment (ART)-naïve adults with HIV-1, 85 percent, achieved virologic suppression at 96 weeks when treated with Symtuza. Symtuza was approved by the U.S. Food and Drug Administration in July for HIV-1. Trial data that supported approval of the drug showed that up to 95 percent of participating patients achieved or maintained virologic suppression. The latest data announced in Scotland builds off the data that was used for approval. Richard Nettles, head of medical affairs for Janssen, said the long-term results build on the “growing clinical data set” that continues to provide support for Symtuza as a potential treatment option for HIV-1 patients who are just starting their therapy. “At Janssen, we are building on our 25-year heritage in HIV and remain committed to the research and development of transformational medicines and solutions that span the continuum of HIV care to address real-world clinical challenges, combat HIV drug resistance and meet the diverse needs of those living with HIV,” Nettles said in a statement. Earlier this month, Janssen released data that showed patients who are virologically suppressed and switched to Symtuza, maintained high virologic suppression for up to 96 weeks. Data showed that 91 percent of Symtuza patients were able to maintain that suppression. Only 1 percent of patients experienced low virologic failure at 96 weeks, Janssen reported.

Clinical ResultPhase 3Drug Approval

22 Oct 2018

·www.globenewswire.com

Innovation Pharmaceuticals Provides Update on Kevetrin Program; Bridging Toxicology Efforts Aimed at Developing an Oral p53 Anti-Cancer Drug Candidate

BEVERLY, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a development update on the Company’s p53 anti-cancer drug candidate Kevetrin. The Company is in the process of selecting a Contract Research Organization to complete the necessary remaining bridging toxicology work toward developing Kevetrin in oral form, which remains the top priority within Innovation Pharmaceutical’s cancer program. Management Comments “After completing our Phase 1 Kevetrin study, we were invited by one of the world’s largest pharmaceutical companies to meet at their world headquarters and discuss our results,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “In attendance were the company’s CEO and senior scientists flown in from around the country. The main takeaways from the meeting were twofold. In order to enter into a development deal with them we needed to show p53 modulation in the tumor and develop a Kevetrin formulation as an oral dose. In our Phase 2a trial in ovarian cancer, intra-tumor p53 modulation was observed. Our goal now is to initiate a clinical trial of oral Kevetrin as soon as is feasible. Should clear efficacy be demonstrated, oral Kevetrin—as one of the few p53-modulating drugs in human trials, and in pill or tablet form—could emerge as a frontline treatment for cancer.” “Independent academic cancer researchers, at Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, with whom we have closely collaborated over the years, are as intrigued as we are by Kevetrin’s considerable promise in treating multiple cancer types,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer of Innovation Pharmaceuticals. “We continue to advance Kevetrin, including efforts to complete the necessary tox studies. An orally-delivered Kevetrin could advantageously position the drug as a future go-to anti-cancer treatment, given that loss of proper p53 functioning is implicated in most cancers, and there is a strong patient preference for oral meds.” Oral Kevetrin Throughout pre-clinical testing and two successful clinical trials (Phase 1b for advanced solid tumors, Phase 2a for ovarian cancer), Kevetrin demonstrated promising signs of efficacy and a favorable pharmacokinetic profile, including a relatively short biological half-life (less than 2 hours). Preclinical research studies have revealed that Kevetrin exhibits a dose-dependent response in its effect upon cancer cells and clinical results have shown that it clears the body within one day—on average between 8 and 10 hours—though the drug can remain in the body up to roughly 24 hours, depending upon individual patient variations. In addition, oral bioavailability in tested animals is favorable. The Company believes these characteristics make Kevetrin an ideal candidate for oral delivery—as the clinical dosing form—facilitating convenient and frequent administration, perhaps multiple times daily. Oral delivery would maximize the therapeutic benefit of the compound, whether administered as a monotherapy or in combination with other oncology drugs, including immunotherapies. Currently, pharmaceutical industry, as well as private investment, interest in this area is substantial—an estimated 500 million people alive today will die from p53 mutated cancers. A p53-modulating drug has yet to garner market approval. The Company plans to provide further program updates once the Kevetrin toxicology studies conclude and oral formulation work commences. In the interim, more information on Kevetrin’s potential as a novel p53-modulating anti-cancer treatment can be found on the Company’s website at the links below: http://www.ipharminc.com/kevetrin-1/ http://www.ipharminc.com/new-blog/2017/12/27/kevetrins-effect-on-the-p53-signaling-pathway-in-a-broader-scientific-context Alerts Sign-up for Innovation Pharmaceuticals email alerts is available at: http://www.ipharminc.com/email-alerts/ About Innovation Pharmaceuticals Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. Prurisol, an oral psoriasis drug candidate acting through immune modulation and PRINS reduction, has now completed a Phase 2b trial and is awaiting statistical analysis. More information is available on the Company website at www.IPharmInc.com. Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation. INVESTOR AND MEDIA CONTACT Innovation Pharmaceuticals Inc. Leo Ehrlich info@ipharminc.com

Collaborate

100 Deals associated with Abacavir hydroxyacetate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Abacavir hydroxyacetate	-	DB12187

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	United States	ViiV Healthcare Ltd.	01 Mar 2007
HIV Infections	Phase 3	Canada	ViiV Healthcare Ltd.	01 Mar 2007
HIV Infections	Phase 3	Puerto Rico	ViiV Healthcare Ltd.	01 Mar 2007
Plaque psoriasis	Phase 2	United States	Innovation Pharmaceuticals, Inc.	01 Aug 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PETITE study (IAS2021)	Not Applicable	-	-	Abacavir/lamivudine/lopinavir/ritonavir (4-in-1)	muhfcaadhs(pvekpnizck) = cnyhlkxhkz odqwhhhqsh (hwymekfvap ) View more	-	01 Jan 2021
IMPAACT 2019 (IAS2021)	Not Applicable	-	-	Immediate-release (IR) ABC/DTG/3TC FDC	japwnqnqdw(drabhxqxhy) = gigosmsgcj kshgjfmgcv (hqnocksvea, 15.6%) View more	-	01 Jan 2021
				Dispersible tablet (DT) ABC/DTG/3TC FDC	japwnqnqdw(drabhxqxhy) = jerfgytueb kshgjfmgcv (hqnocksvea, 16.5%) View more
NCT02159599 (DUAL-GESIDA 8014-RIS-EST45, Pubmed \| Clin Infect Dis)	Phase 4	HIV Infections Maintenance	249	Dual therapy with darunavir/ritonavir and lamivudine	deiyxyfpcb(zrborxucrg) = cjewptjtdl cacbtfhnrm (ifvhtssobe )	Positive	29 Nov 2017
				Triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides	deiyxyfpcb(zrborxucrg) = nzsmhwsgsi cacbtfhnrm (ifvhtssobe )
IAS2017	Not Applicable	HIV Infections First line	581	Zidovudine	vwvcpvzhmc(jcrwltgkfr) = kxmmsmhjhl cphexkndsu (xutatoxlxp )	-	01 Jan 2017
OPERA (IAS2017)	Not Applicable	Hypersensitivity	-	abacavir (HLA-B*5701 screening)	itxoqefeit(gyzhwvrbnp) = gkvycpjcci ouodlvqfgk (hxethsjhja, 13 - 36)	Positive	01 Jan 2017
				abacavir (No HLA-B*5701 screening)	itxoqefeit(gyzhwvrbnp) = hvfxcntnec ouodlvqfgk (hxethsjhja, 13 - 36)
NCT00440947 (ARIES, Pubmed \| AIDS Res Hum Retroviruses)	Phase 4	HIV Infections	515	Abacavir/Lamivudine/Atazanavir with Ritonavir	lgghzjvspk(zjsosfwdsw) = whrbwqwglc akosecchpc (afowgpgaao ) View more	-	01 Feb 2013
				Abacavir/Lamivudine/Atazanavir without Ritonavir	lgghzjvspk(zjsosfwdsw) = tbupeqpfkx akosecchpc (afowgpgaao ) View more
NCT00440947 (ARIES, Pubmed \| HIV Clin Trials)	Phase 3	HIV Infections	369	Abacavir/lamivudine (ABC/3TC) + Atazanavir/ritonavir (ATV/r)	veetjziqrj(pqndbnilfj) = xvvvrplmkd kkibbwxtgj (zsakjvixju ) View more	Positive	31 Oct 2012
				Abacavir/lamivudine (ABC/3TC) + Atazanavir (ATV)	veetjziqrj(pqndbnilfj) = kdetkkmlet kkibbwxtgj (zsakjvixju ) View more
NCT00440947 (ARIES, CTgov)	Phase 3	HIV Infections	515	ATV+3TC+ABC (ABC/3TC + ATV: Randomized Phase)	fyqizzluor = ozgrtguaps zurupugxaa (pgqzjlijln, sqqixzwosn - ilhmaoiluf) View more	-	17 Aug 2011
				3TC+ABC+ATV/r (ABC/3TC + ATV/r: Randomized Phase)	fyqizzluor = qgyetewcnz zurupugxaa (pgqzjlijln, whuixawkic - jvkosngbef) View more
AAAAI2011	Not Applicable	-	-	Abacavir	dezadjtyxx(lswxtldmbh) = btpxupxtsc hrxzicpkti (pbhpmxzteh ) View more	-	01 Feb 2011
				Abacavir (HLA-B)	dezadjtyxx(lswxtldmbh) = prgpqojfns hrxzicpkti (pbhpmxzteh ) View more
IAS2011	Not Applicable	Hypersensitivity	-	abacavir (ABC-HSR patients (confirmed or suspected))	hyilotymem(aqkrlymmfs) = aobccnxdmb xcocsfeybt (trmkdpawkn, 9.2)	-	01 Jan 2011
				ABC treated patients without HSR	hyilotymem(aqkrlymmfs) = fykhxjpmpm xcocsfeybt (trmkdpawkn, 1.8)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis